头颈部鳞状细胞癌的非手术治疗进展

摘要/Abstract

摘要：局部晚期头颈部鳞状细胞癌需要采用多学科治疗的方法，包括手术+放疗、伴或不伴化疗以及同步放化疗。诱导化疗目前仍存在争议。靶向药物西妥昔单抗已在头颈部鳞状细胞癌的治疗中取得满意的效果。针对程序性死亡蛋白-1及其配体的抑制剂也显示出显著的功效，然而，只有少数患者可以从单药治疗中受益。为提高免疫疗效，联合免疫治疗成为可选策略。

关键词:头颈部肿瘤,放射疗法,西妥昔单抗,免疫疗法,化学疗法

Abstract:Locally advanced head and neck squamous cell carcinoma requires a multidisciplinary approach, including surgery followed by radiotherapy, with or without chemotherapy, or definitive concurrent chemoradiotherapy. The application of induction chemotherapy remains controversial. Cetuximab has achieved satisfactory results in the treatment of head and neck squamous cell carcinoma. Immunocheckpoint inhibitors against the receptor programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have demonstrated clinical efficacy in head and neck squamous carcinoma. However, only a small subset of patients can benefit from anti-PD-1 and anti-PD-L1 monotherapy. To improve the effectiveness of immunotherapy, combined of immunotherapy and other treatments has become an alternative strategy.

Key words:Head and neck neoplasms,Radiotherapy,Cetuximab,Immunotherapy,Chemotherapy

臧守梅, 严丹方, 严森祥. 头颈部鳞状细胞癌的非手术治疗进展[J]. 国际肿瘤学杂志, 2019, 46(12): 741-744.

Zang Shoumei, Yan Danfang, Yan Senxiang. Advances in nonsurgical treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2019, 46(12): 741-744.

参考文献［28］

［1］	Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and itsimmunotherapeutic implications［J］. JCI Insight, 2016, 1 (17): e89829. DOI: 10.1172/jci.insight.89829.
［2］	Argiris A, Harrington KJ, Tahara M, et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck［J］. Front Oncol, 2017, 7: 72. DOI: 10.3389/fonc.2017.00072.
［3］	Lin W, Chen M, Hong L, et al. Crosstalk between PD-1/PD-L1 blockade and its combinatorial therapies in tumor immune microenvironment: a focus on HNSCC［J］. Front Oncol, 2018, 8: 532. DOI: 10.3389/fonc.2018.00532.
［4］	Semrau R. The role of radiotherapy in the definitive and postoperative treatment of advanced head and neck cancer［J］. Oncol Res Treat, 2017, 40(6): 347-352. DOI: 10.1159/000477128.
［5］	Leclerc M, Lartigau E, Lacornerie T, et al. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy［J］. Radiother Oncol, 2015, 116(1): 87-93. DOI: 10.1016/j.radonc.2015.06.007.
［6］	Margalit DN, Haddad RI, Tishler RB, et al. A phase 1 study of afatinib in combination with postoperative radiation therapy with and without weekly docetaxel in intermediate and high-risk patients with resected squamous cell carcinoma of the head and neck［J］. Int J Radiat Oncol Biol Phys, 2019, 105(1): 132-139. DOI: 10.1016/j.ijrobp.2019.04.034.
［7］	Jones TM, De M, Foran B, et al. Laryngeal cancer: United Kingdom National Multidisciplinary guidelines［J］. J Laryngol Otol, 2016, 130(S2): S75-S82. DOI: 10.1017/S0022215116000487.
［8］	Ghosh-Laskar S, Kalyani N, Gupta T, et al. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: results of a prospective randomized trial［J］. Head Neck, 2016, 38(2): 202-207. DOI: 10.1002/hed.23865.
［9］	Lee SY, Choi YS, Song IC, et al. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: a multicenter retrospective analysis［J］. Medicine (Baltimore), 2018, 97(21): e10778. DOI: 10.1097/MD.0000000000010778.
［10］	Szturz P, Wouters K, Kiyota N, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data［J］. Oncologist, 2017, 22(9): 1056-1066. DOI: 10.1634/theoncologist.2017-0015.
［11］	Popovtzer A, Burnstein H, Stemmer S, et al. Phase Ⅱ organ-preservation trial: concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy［J］. Head Neck, 2017, 39(2): 227-233. DOI: 10.1002/hed.24571.
［12］	Busch CJ, Tribius S, Schafhausen P, et al. The current role of systemic chemotherapy in the primary treatment of head and neck cancer［J］. Cancer Treat Rev, 2015, 41(3): 217-221. DOI: 10.1016/j.ctrv.2015.02.002.
［13］	Hitt R, Grau JJ, López-Pousa A, et al. A randomized phase Ⅲ trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer［J］. Ann Oncol, 2014, 25(1): 216-225. DOI: 10.1093/annonc/mdt461.
［14］	Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. a phase Ⅱ-Ⅲ trial［J］. Ann Oncol, 2017, 28(9): 2206-2212. DOI: 10.1093/annonc/mdx299.
［15］	Kim R, Hahn S, Shin J, et al. The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: a meta-analysis［J］. Cancer Res Treat, 2016, 48(3): 907-916. DOI: 10.4143/crt.2015.359.
［16］	Santuray RT, Johnson DE, Grandis JR. New therapies in head and neck cancer［J］. Trends Cancer, 2018, 4(5): 385-396. DOI: 10.1016/j.trecan.2018.03.006.
［17］	Granados-García M, Aguilar-Ponce JL, Maldonado-Magos F, et al. Advanced squamous cell carcinoma of the head and neck: the current role of cetuximab［J］. ORL J Otorhinolaryngol Relat Spec, 2016, 78(6): 320-333. DOI: 10.1159/000455891.
［18］	Colevas AD, Yom SS, Pfister DG, et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018［J］. J Natl Compr Canc Netw, 2018, 16(5): 479490. DOI: 10.6004/jnccn.2018.0026.
［19］	Mazorra Z, Lavastida A, Concha-Benavente F, et al. Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T Cells in head and neck cancer patients［J］. Front Pharmacol, 2017, 8: 382. DOI: 10.3389/fphar.2017.00382.
［20］	Chen Z, Xu XH. Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma［J］. Saudi Med J, 2015, 36(6): 659-664. DOI: 10.15537/smj.2015.6.11460.
［21］	Vassilakopoulou M, Psyrri A, Argiris A, et al. Targeting angiogenesis in head and neck cancer［J］. Oral Oncol, 2015, 51(5): 409-415. DOI: 10.1016/j.oraloncology.2015.01.006.
［22］	Ferris RL. Immunology and immunotherapy of head and neck cancer［J］. J Clin Oncol, 2015, 33(29): 3293-3304. DOI: 10.1200/JCO.2015.61.1509.
［23］	Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck［J］. N Engl J Med, 2016, 375(19): 1856-1867. DOI: 10.1056/NEJMoa-1602252.
［24］	Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study［J］. Lancet, 2019, 393(10167): 156-167. DOI: 10.1016/S0140-6736(18)31999-8.
［25］	Burtness B, Harrington KJ, Greil R, et al. LBA8_PRKEYNOTE-048: phase Ⅲ study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)［J］. Ann Oncol, Munich, 2018, 29(suppl_8). DOI: 10.1093/annonc/mdy424.045.
［26］	Wise-Draper TM, Old MO, Worden FP, et al. Phase Ⅱ multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma［J］. J Clin Oncol, 2018, 36(15_suppl): 6017. DOI: 10.1200/JCO.2018.36.15_suppl.6017.
［27］	Dong ZY, Zhang JT, Liu SY, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer［J］. Oncoimmunology, 2017, 6(11): e1356145. DOI: 10.1080/2162402X.2017.1356145.
［28］	Hata A, Katakami N, Nanjo S, et al. Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer［J］. Oncotarget, 2017, 8(69): 113807-113816. DOI: 10.18632/oncotarget.22837.

[1]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	陈琦, 徐晨阳, 王寅, 雷大鹏.高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[4]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[5]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[6]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[7]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[8]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[9]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[10]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[11]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[12]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[13]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[14]	崔腾璐, 吕璐, 孙鹏飞.放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[15]	陈欣祎, 翁一鸣, 魏家燕, 王劲松, 彭敏.免疫检查点抑制剂在复发或转移性头颈部鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(9): 553-557.